{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T23:12:11Z","timestamp":1743030731850,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":23,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071623756"},{"type":"electronic","value":"9781071623763"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2376-3_11","type":"book-chapter","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:17:05Z","timestamp":1655986625000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-\u03b3-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells"],"prefix":"10.1007","author":[{"given":"Louisa L.","family":"Wiede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Drover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"4","key":"11_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.semcancer.2012.03.003","volume":"22","author":"J Bukur","year":"2012","unstructured":"Bukur J, Jasinski S, Seliger B (2012) The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22(4):350\u2013358","journal-title":"Semin Cancer Biol"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","volume":"101","author":"B Seliger","year":"2008","unstructured":"Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249\u2013276","journal-title":"Adv Cancer Res"},{"issue":"4","key":"11_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","volume":"75","author":"D Ostroumov","year":"2018","unstructured":"Ostroumov D, Fekete-Drimusz N, Saborowski M, K\u00fchnel F, Woller N (2018) CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci 75(4):689\u2013713","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"11_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10549-019-05195-y","volume":"175","author":"AF de Groot","year":"2019","unstructured":"de Groot AF, Blok EJ, Charehbili A, Engels CC, Smit VTHBM, Dekker-Ensink NG, Putter H, Meershoek-Klein Kranenbarg E, van de Velde CJH, Liefers GJ, Nortier JWR, Kuppen PJK, van der Burg SH, Kroep JR (2019) Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 175(3):605\u2013615","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"11_CR5","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.3892\/ol.2017.6784","volume":"14","author":"JA Rodr\u00edguez","year":"2017","unstructured":"Rodr\u00edguez JA (2017) HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncol Lett 14(4):4415\u20134427","journal-title":"Oncol Lett"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/BD-2004-20112","volume":"20","author":"M Campoli","year":"2004","unstructured":"Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S (2004) HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 20:105\u2013125","journal-title":"Breast Dis"},{"issue":"5","key":"11_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00005-012-0185-y","volume":"60","author":"KK Payne","year":"2012","unstructured":"Payne KK, Manjili MH (2012) Adaptive immune responses associated with breast cancer relapse. Arch Immunol Ther Exp 60(5):345\u2013350","journal-title":"Arch Immunol Ther Exp"},{"issue":"3","key":"11_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/B:CLIN.0000037707.07428.ff","volume":"21","author":"M Saio","year":"2004","unstructured":"Saio M, Teicher M, Campbell G, Feiner H, Delgado Y, Frey AB (2004) Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 21(3):243\u2013249","journal-title":"Clin Exp Metastasis"},{"doi-asserted-by":"publisher","unstructured":"Algarra I, Garrido F, Garcia-Lora AM (2021) MHC heterogeneity and response of metastases to immunotherapy. Cancer Metastasis Rev. https:\/\/doi.org\/10.1007\/s10555-021-09964-4","key":"11_CR9","DOI":"10.1007\/s10555-021-09964-4"},{"issue":"1","key":"11_CR10","first-page":"3","volume":"2","author":"F Garrido","year":"1991","unstructured":"Garrido F, Ruiz-Cabello F (1991) MHC expression on human tumors--its relevance for local tumor growth and metastasis. Semin Cancer Biol 2(1):3\u201310","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"11_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ijc.11497","volume":"108","author":"A Choudhury","year":"2004","unstructured":"Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2\/neu gene, upregulates HLA class I and induces apoptosis of Her2\/neu positive tumor cell lines. Int J Cancer 108(1):71\u201377","journal-title":"Int J Cancer"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","volume":"39","author":"S Escriv\u00e1-de-Roman\u00ed","year":"2018","unstructured":"Escriv\u00e1-de-Roman\u00ed S, Arum\u00ed M, Bellet M, Saura C (2018) HER2-positive breast cancer: current and new therapeutic strategies. Breast 39:80\u201388","journal-title":"Breast"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-med-042513-015127","volume":"66","author":"MF Rimawi","year":"2015","unstructured":"Rimawi MF, Schiff R, Osborne CK (2015) Targeting HER2 for the treatment of breast cancer. Annu Rev Med 66:111\u2013128","journal-title":"Annu Rev Med"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","volume":"67","author":"R Duchnowska","year":"2018","unstructured":"Duchnowska R, Loibl S, Jassem J (2018) Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev 67:71\u201377","journal-title":"Cancer Treat Rev"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https:\/\/doi.org\/10.1155\/2014\/852748","journal-title":"Mol Biol Int"},{"issue":"10","key":"11_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","volume":"41","author":"V D\u2019Amato","year":"2015","unstructured":"D\u2019Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R (2015) Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev 41(10):877\u2013883","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"11_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/onc.2008.432","volume":"28","author":"M Scaltriti","year":"2009","unstructured":"Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28(6):803\u2013814","journal-title":"Oncogene"},{"issue":"12","key":"11_CR18","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.4049\/jimmunol.1301597","volume":"191","author":"K Mimura","year":"2013","unstructured":"Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K (2013) The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol 191(12):6261\u20136272","journal-title":"J Immunol"},{"issue":"12","key":"11_CR19","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1541-7786.MCR-19-0545","volume":"17","author":"S Chandrasekaran","year":"2019","unstructured":"Chandrasekaran S, Sasaki M, Scharer CD, Kissick HT, Patterson DG, Magliocca KR, Seykora JT, Sapkota B, Gutman DA, Cooper LA, Lesinski GB, Waller EK, Thomas SN, Kotenko SV, Boss JM, Moreno CS, Swerlick RA, Pollack BP (2019) Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression. Mol Cancer Res 17(12):2395\u20132409","journal-title":"Mol Cancer Res"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"5.1.1","DOI":"10.1002\/cpim.40","volume":"120","author":"KM McKinnon","year":"2018","unstructured":"McKinnon KM (2018) Flow cytometry: an overview. Curr Protoc Immunol 120:5.1.1\u20135.1.11","journal-title":"Curr Protoc Immunol"},{"issue":"12","key":"11_CR21","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.humimm.2004.09.005","volume":"65","author":"DR Spurrell","year":"2004","unstructured":"Spurrell DR, Oldford SA, Frost T, Larsen B, Codner D, Edgecombe A, Drover S (2004) Discordant expression of HLA class II-associated co-chaperones and HLA-DRB alleles in cultured fibroblast-like synoviocytes. Hum Immunol 65(12):1516\u20131529","journal-title":"Hum Immunol"},{"issue":"1","key":"11_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087377","volume":"9","author":"AA Mostafa","year":"2014","unstructured":"Mostafa AA, Codner D, Hirasawa K, Komatsu Y, Young MN, Steimle V, Drover S (2014) Activation of ER\u03b1 signaling differentially modulates IFN-\u03b3 induced HLA-class II expression in breast cancer cells. PLoS One 9(1):e87377","journal-title":"PLoS One"},{"issue":"1","key":"11_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0092-8674(78)90296-9","volume":"14","author":"CJ Barnstable","year":"1978","unstructured":"Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14(1):9\u201320","journal-title":"Cell"}],"container-title":["Methods in Molecular Biology","Cancer Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2376-3_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:20:13Z","timestamp":1655986813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2376-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071623756","9781071623763"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2376-3_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"24 June 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}